Chimerix Company Profile
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. The companys lead product candidate is brincidofovir (CMX001), a nucleotide analog, which is in Phase III clinical trials for the prevention of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant (HCT) recipients and in kidney transplant recipients, as well as to treat adenovirus infection in allogeneic HCT patients. It is also developing CMX157, a nucleotide analog that is in Phase II clinical stage for the treatment of HIV and hepatitis B virus infection. The companys preclinical testing product comprises CMX669, a compound with in vitro activity for the treatment of BK virus and CMV. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.